InvestorsHub Logo
Followers 154
Posts 2652
Boards Moderated 0
Alias Born 01/29/2004

Re: BIOChecker4 post# 361105

Monday, 05/23/2022 3:37:10 PM

Monday, May 23, 2022 3:37:10 PM

Post# of 463618
Except, of course, for Anavex.

Just because something hasn’t worked yet doesn’t mean it won’t.


Except, of course, for here, the totally "biochecked" Anavex sigma-1 receptor activation mechanism. No chance for that at all. The lack of FDA-acceptable double-blind clinical trials for blarcamesine proves it. Won't, can't work. I'm gonna lose my small AVXL investment. So little did I know; so much I ignorantly hoped for.

Anavex is exceptional in every regard. Will be the only drug example where something that didn't work before won't work ever. Biochecking has shown this, from the start.

Please, feel sorry for me and all the other believers in the Anavex mechanism of action. Currently (well, for years) we just sit around anxiously twiddling our thumbs, awaiting the bad, defining Phase 3 clinical results that will, finally, end the Anavex story. Complete failure, biochecked for sure.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News